Results 81 to 90 of about 3,139,231 (313)

Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here? [PDF]

, 2007
Angelo Paradiso, Anita Mangia, Amalia Azzariti, Stefania Tommasi   +3 more
openalex   +1 more source

3:27 PM Abstract No. 35 Factors affecting outcomes of ablation for oligometastatic breast cancer: the importance of ablation margins [PDF]

, 2020
Fourat Ridouani, Sanjeev Solomon, Yolanda Bryce, Jacqueline Bromberg, Constantinos T. Sofocleous, Ryan W. England, Amy R. Deipolyi   +6 more
openalex   +1 more source

Function‐driven design of a surrogate interleukin‐2 receptor ligand

FEBS Letters, EarlyView.
Interleukin (IL)‐2 signaling can be achieved and precisely fine‐tuned through the affinity, distance, and orientation of the heterodimeric receptors with their ligands. We designed a biased IL‐2 surrogate ligand that selectively promotes effector T and natural killer cell activation and differentiation. Interleukin (IL) receptors play a pivotal role in
Ziwei Tang, Zelin Cheng, Teng Li, Fulian Wang, Liangminghui Zhang, Xiuxiu He, Lili Liu, Wei Wang, Aibin Liang, Guang Yang   +9 more
wiley   +1 more source

P405: INHIBITION OF CKS1-DEPENDENT PROTEOSTASIS REVEALS VULNERABILITIES IN LEUKAEMIC STEM CELLS WITH CONCOMITANT PROTECTION OF HEALTHY HAEMATOPOIETIC STEM CELLS

HemaSphere, 2022
W. Grey, A. Rio-Machin, P. Casado-Izquierdo, E. Gronroos, S. Ali, J. Miettinen, F. Bewicke-Copley, A. Parsons, C. Heckman, C. Swanton, P. Cutillas, J. Gribben, J. Fitzgibbon, D. Bonnet   +13 more
doaj   +1 more source

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. [PDF]

ESMO Open, 2022
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW.   +20 more
europepmc   +1 more source

Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions

FEBS Letters, EarlyView.
Mutant p53 gain‐of‐function is thought to be mediated by interaction with other transcription factors. We identify multiple ETS transcription factors that can bind mutant p53 and found that this interaction can be promoted by a PXXPP motif. ETS proteins that strongly bound mutant p53 were upregulated in ovarian cancer compared to ETS proteins that ...
Stephanie A. Metcalf, Nicholas F. Downing, Kaitlyn M. Mills, Samuel C. Metcalfe, Alexander E. Kritzer, Lindsey D. Mayo, Peter C. Hollenhorst   +6 more
wiley   +1 more source

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE

HemaSphere, 2023
Gamal Sayed, Sarah Elkourashy, Dina Soliman, Naela Al Mallahi, Awni Alshurafa, Amna Gamil, Firyal Ibrahim, Mohammed Alnajjar, Shehab Mohamed   +8 more
doaj   +1 more source

Adjuvant treatment can improve prognosis in patients with non-small cell lung cancer ≤3 cm after sublobectomy: a propensity score analysis. [PDF]

J Thorac Dis, 2021
Ma H, Cheng J, Yu Y, Liu B, Qin J, Xing W, Luo S.   +6 more
europepmc   +1 more source

The newfound relationship between extrachromosomal DNAs and excised signal circles

FEBS Letters, EarlyView.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study

Journal for ImmunoTherapy of Cancer
Background Immune checkpoint inhibitors (ICIs) have led to enduring responses in subsets of patients with cancer. However, these responses carry the risk of immune-related adverse events (irAEs), which can diminish the overall benefit of ICI treatment ...
Lisa H Butterfield, John E Connolly, Nicholas L Bayless, Jeffrey A Bluestone, Samantha Bucktrout, Aik Choon Tan, Kevan C Herold, Zoe Quandt, Anastasia Lucas, Arabella Young, Christine N Spencer, Lacey J Padron, Samantha I Liang, EnJun Yang, Samantha Stone, Muhammad Zaki Hidayatullah Fadlullah, Sara Siebel Marr, Marshall A Thompson, Mark S Anderson   +18 more
doaj   +1 more source